Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

33.3%

2 terminated/withdrawn out of 6 trials

Success Rate

60.0%

-26.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

167%

5 of 3 completed trials have results

Key Signals

5 with results

Enrollment Performance

Analytics

Phase 1
6(100.0%)
6Total
Phase 1(6)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT07158437Phase 1Active Not Recruiting

Phase 1 Study of SL-325 in Healthy Volunteers

Role: lead

NCT05275439Phase 1Terminated

Phase 1 Study of Shattuck Labs (SL)-172154 in Subjects With MDS or AML

Role: lead

NCT05483933Phase 1Completed

Phase 1b Study of SL-172154 Administered With Combination Agent(s) in Subjects With Ovarian Cancers

Role: lead

NCT03894618Phase 1Completed

SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas

Role: lead

NCT04502888Phase 1Terminated

Ph1 Study of SL-172154 Administered Intratumorally in Subjects With Squamous Cell Carcinoma of the Head and Neck or Skin

Role: lead

NCT04406623Phase 1Completed

Phase 1 Study of SL-172154 (SIRPα-Fc-CD40L) in Subjects With Ovarian Cancer

Role: lead

All 6 trials loaded